Nephron SC Inc. - 634647 - 10/11/2022

Quick Take

The FDA has issued a formal warning letter to Nephron SC Inc. following an inspection that identified significant violations of Current Good Manufacturing Practice (CGMP) regulations. Because these finished pharmaceuticals were produced under substandard conditions, the agency has classified the products as adulterated, signaling potential risks to safety, identity, and quality.

Why It Matters

When the FDA labels a facility's products as adulterated, it indicates a systemic failure in the manufacturing process that could compromise sterile integrity or drug potency. For eye care professionals and surgical centers that may utilize products from this manufacturer, this regulatory action serves as a critical alert regarding the reliability of the supply chain. Such warnings often precede product recalls or significant market shortages, requiring practices to stay vigilant about the medications they stock and administer.

Key Details

• The FDA issued Warning Letter 634647 to Nephron SC Inc. on October 11, 2022.
• The facility failed to meet Current Good Manufacturing Practice (CGMP) requirements for finished pharmaceuticals.
• Products manufactured at the site are legally considered 'adulterated' under the Federal Food, Drug, and Cosmetic Act.
• The warning indicates that the company's quality control or manufacturing environments did not provide sufficient assurance of product safety.

Practice Implications

Clinicians and practice managers should review their inventory for any finished pharmaceuticals manufactured by Nephron SC Inc. and consider alternative suppliers if safety concerns persist. It is essential to monitor for any follow-up recall notices and to report any unexpected adverse events or product defects to the FDA’s MedWatch program.

Who's Affected

What's Next

Nephron SC Inc. must provide the FDA with a comprehensive plan to correct the identified CGMP violations. The industry should watch for further regulatory actions, such as import alerts or product seizures, if the company fails to demonstrate adequate remediation of its manufacturing processes.